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A B S T R A C T
Purpose: This study investigated whether interictal epileptiform discharges (IED) on a baseline routine
EEG in children with ADHD was associated with the occurrence of epileptic seizures (Sz) or inﬂuenced
the use of methylphenidate (MPH) during 2 years follow-up.
Methods: A retrospective chart-review of 517 ADHD children with EEG revealed IED in 39 cases. These
patients (IED group) were matched on age and gender with 39 patients without IED (non-IED group). We
measured at baseline, 1 year and 2 years Sz occurrence, the use of MPH and antiepileptic drug (AED).
Results: At baseline, 12 patients in the IED group had active epilepsy and three of them had Sz during the
last year. 36 (92.3%) patients were treated with MPH. Initial positive response to MPH was achieved in
83.3% compared with 89.2% in the non-IED group. At 1 and 2 years follow-up, three patients who also had
Sz at baseline and difﬁcult to treat epilepsy, had Sz, without changes in seizure frequency. We found no
statistically signiﬁcant differences between the groups with respect to MPH use at 1 year and at 2 years.
Ten patients from IED group, who did not have conﬁrmed epilepsy diagnosis, temporarily used AEDs
during the ﬁrst year of follow-up.
Conclusion: Despite the occurrence of IED, the use of MPH was safe during 2 years follow-up. IED predict
the Sz occurrence in children with previous epilepsy, but does not necessarily suggest an increased
seizure risk. A caution is warranted in order not to overestimate the signiﬁcance of temporarily
occurrence of IED.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Interictal epileptiform discharges (IED) on EEG may occur in
children with attention deﬁcit/hyperactivity disorder (ADHD) and
contribute to the occurrence of ADHD symptoms [1]. ADHD in
children is reported to be a risk factor for incident unprovoked
seizures and epilepsy [2], and suggested to predispose for epilepsy
development as do autism spectrum disorder and cerebral palsy
[3–5]. EEGs performed in children with new onset seizures show
IED in approximately 18–50%, and IED occurrence is predictive of* Corresponding author at: Stavanger University Hospital, Division of Psychiatry,
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epilepsy [6]. However, the prognostic value of IED in ADHD
children with and without previous epilepsy, regarding occurrence
of seizure during early illness course, is unknown [7].
Methylphenidate (MPH) is the psychostimulant drug most
frequently used for the treatment of ADHD and there is
overwhelming evidence for its beneﬁt [8–10]. It is considered to
be safe in children without epilepsy. On the other hand, there is
limited research about the use of MPH in patients with epilepsy
[11–15] and children with ADHD and IED [16]. A recent study
found that clinicians appeared to be reluctant to diagnose and
initiate treatment for ADHD in children with epilepsy [17]. It is
thus of clinical importance whether it is safe to use MPH in ADHD
with IED.
The aims of the present study were to investigate whether IED
occurrence at ADHD assessment could predict the occurrence ofserved.
Table 1
ADHD patients with and without IED at baseline.
Demographics IED-group
(n = 39)
Non-IED
group (n = 39)
p-Value
Age, mean  SD 9.7  2.7 9.7  2.7
Gender, female (%) 11 (28.2%) 11 (28.2)
Developmental disorders 22/39 (56.4%) 17/39 (43.6%) 0.26
IQ >85 (%) 21/38 (55.3%) 23/34 (67.6%) 0.28
ADHD-I (%) 16/39 (41%) 6/39 (15.4%) 0.01
Epilepsy 12/39 (30.8%) 0
Sz during the last 5 years 12/12 (100%) 0
Sz during the last year 3/12 (25%) 0
MPH, at baseline 36/39 (92.3%) 37/39 (94.9%) 0.64
MPH, positive response 30/36 (83.3%) 33/37 (89.2%) 0.47
ADHD-I, ADHD predominantly inattentive subtype; MPH, methylphenidate; IED,
interictal epileptiform discharges; IQ, intelligence quotient; Sz, epileptic seizures.
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follow-up.
2. Materials and methods
2.1. Participants and procedure
Our study was conducted at Stavanger University Hospital on
consecutive patients admitted to assessment during a 6 years
period; January 2000–December 2005. We carried out a retro-
spective chart review of all patients aged 5–14 who were
diagnosed with ADHD in accordance with DSM-IV TR [18]. For
details see previous publications [7,15]. A digitized 20 min routine
awake EEG with 21 electrodes (10–20 system) including hyper-
ventilation and photic stimulation was performed. The EEGs were
classiﬁed as either epileptiform or nonepileptiform according to
the presence or absence of IED. IED were deﬁned as spikes or spike-
wave complexes, isolated or occurring serially (in runs) without
evident clinical signs of a Sz. The IED index was estimated as
percentage of time in three categories (0%, <1%, 1%). Sz, epilepsy
and epileptic syndromes were diagnosed according to the
classiﬁcation system of the International League Against Epilepsy
[19–21]. Sz frequency during the last year was deﬁned as Sz free,
1–12 Sz per year, and >12 Sz per year, and antiepileptic drug (AED)
treatment was classiﬁed as untreated, monotherapy or polyther-
apy. We also analyzed data about comorbid disorders of
psychological development and IQ level (IQ > 85, IQ < 85).
We were able to carry out EEG at baseline in 517 out of
607 cases (85.4%), and 39 cases (7.5%) had IED. We studied 2 years
follow-up of these 39 cases (IED group) and compared them with
39 randomly selected cases matched for age and gender without
EA (non-IED group). At baseline, 1 and 2 years we measured the Sz
occurrence and frequency, the use of AEDs, and the use of MPH.
MPH was administered according to the Norwegian Guidelines
[22], in dosage 0.5–1.2 mg per kilo either three times daily (short-
acting MPH) or once per day (slow- acting MPH). During titration
with MPH the use of AEDs was stable. The response to MPH was
evaluated after several weeks of treatment (4–6 weeks). The
response was considered positive if signiﬁcant reduction in ADHD
symptoms scores assessed with ADHD IV rating scale was found
[23], in addition to parents and teachers observations. During
follow-up we registered whether MPH was given or not. In the IED
group at least one follow-up EEG was carried out, an additional
sleep EEG was performed in 15 cases and long-term video-EEG
monitoring in ﬁve cases because of diagnostic difﬁculties (suspect
Sz).
2.2. Statistical analyses
Continuous demographic and clinical variables in subjects with
and without IED were compared using Student’s t-tests for
continuous and symmetrically distributed data and Mann–
Whitney tests for continuous and skewed data. Proportions were
compared using Chi-squared test or Fisher’s exact test. Methods for
matched samples (paired-samples t-tests, McNemar’s tests) were
also applied. However, the application of methods for matched
samples did not alter the conclusions. A p-value of <0.05 was
considered statistically signiﬁcant.
2.3. Approval
The study was approved by the Norwegian Data Inspectorate
and by the Regional Committee on Medical Research Ethics in
region West (nr. 010.07). The study was performed in accordance
with ethical standards of the Declaration of Helsinki. Written
informed consent was obtained from parents.3. Results
3.1. Demographic and clinical characteristics at baseline
Due to matching procedures there were no differences between
the groups regarding age and gender. Proportion of disorders of
psychological development or IQ level >85 showed also no
differences (Table 1). As reported in previous publications we
found that, among the 39 children with IED, 54% had generalized
IED, 41% had focal IED, and 5% had mixed IED [7]. The majority 36/
39 (92%) of cases with IED had short duration of IED, the IED index
was <1%. The IED group had signiﬁcantly more often predomi-
nantly inattentive subtype of ADHD (41%) compared to the non-
IED group (15.4%). In the IED group 12 patients had epilepsy with
recent seizures (Sz) (last 5 years). During the last year, nine
patients were seizure free, two had 1–12 Sz and one had more than
12 Sz. We found that 75% (9/12) had localization-related epilepsy
and 25% generalized epilepsy. All patients with epilepsy received
AEDs; 10 monotherapy and two polytherapy. No patients in the
non-IED group had epilepsy.
At baseline, 36/39 (92.3%) patients with IED were treated with
MPH. The three patients that were not given MPH had no previous
epilepsy. Initial positive response to MPH was achieved in 30/36
(83.3%) of children with IED; 10/12 (83.3%) of the children with
epilepsy and 20/24 (83.3%) of the cases without epilepsy. In the
non-IED group of the 37 initially treated cases, 33/37 (89.2%) had
positive effect of MPH treatment.
3.2. 1 and 2 years follow-up
At 1 and 2 years follow-up only three patients, all from IED
group, had experienced Sz (Table 2). These three patients had
pharmacoresistant epilepsy at baseline and had no change in
seizure frequency. We found no signiﬁcant differences regarding
the use of MPH. Within the IED group we did not ﬁnd statistically
signiﬁcant differences between the cases with and without
epilepsy regarding use of MPH at 1 and 2 years follow-up (Table 3).
At 1 year follow-up 22 patients in the IED group were treated
with AEDs, 12 of them had epilepsy (monotherapy 10, polytherapy
two cases). At 2 years 12 children from IED group used AEDs, 10 of
them had epilepsy (eight monotherapy, two polytherapy). During
follow-up we carried out control EEG in the IED group (one case
missing). We found IED in 12 (31.2%) cases; focal in 10 and
generalized in 2. In the IED-cases with epilepsy, four cases had only
focal IED.
4. Discussion
The main ﬁnding of this study was that it seems to be safe to
give MPH to patients with ADHD even if they have IED on routine
Table 2
1 and 2 years follow-up.
IED-group
(n = 39)
Non-IED
group (n = 39)
p-Value
Age, mean  SD 9.7  2.7 9.7  2.7
Gender, female (%) 11 (28.2%) 11 (28.2%)
1 year
Sz occurrence 3 0
MPH 28/36 (77.8%) 33/37 (89.2%) 0.19
AED monotherapy 20 0
AED polytherapy 2 0
2 years
Sz occurrence 3 0
MPH 26/36 (72.2%) 27/37 (73%) 0.49
AED monotherapy 10 0
AED polytherapy 2 0
AED, antiepileptic drug; MPH, methylphenidate; IED, interictal epileptiform
discharges; Sz, epileptic seizure.
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Sz during 2 years follow-up. Among children with IED, Sz did occur
only in those with a previous history of difﬁcult to treat epilepsy.
No other cases in this study had Sz during follow-up. The use of
MPH was similar in the both groups (with and without IED).
4.1. Seizure risk in ADHD children with IED and the use of MPH and
AEDs
The seizure risk in ADHD children with IED in the EEG has been
discussed in some publications [11,24]. Hemmer et al. [24]
investigated the seizure risk in non-epileptic patients with ADHD
who used stimulants. The patients were diagnosed between
1993 and 1998 and were followed either by ofﬁce visit or by
telephone in 1999. They found that three out of 30 patients with IED
had a seizure during follow-up. The patients had long latencies to
seizure occurrence, (10 months, 14 months and 3 years). They
concluded that epileptiform EEG in patients with ADHD was
suggested to predict considerable risk for the eventual occurrence
of seizure. In contrast to their study, none of our 27 children with IED
without previous history of epilepsy, developed seizure during
follow-up. In addition, seizure frequency in cases with active
epilepsy, did not change from baseline. Our ﬁnding is concordant
with the study by Gucuyener et al. [11], which investigated use of
MPH for ADHD in patients with epilepsy or EEG abnormalities. In this
study a subgroup of 15 nonepileptic patients had epileptiform EEG at
baseline and none of them had a seizure during the study period ofTable 3
39 ADHD patients with IED.
Demographics IED-epilepsy
(n = 12)
IED-non-epilepsy
(n = 27)
p-Value
Age, mean  SD 8.5  2.3 10.3  2.7
Gender, female (%) 3 (25%) 8 (29.6%)
MPH at baseline n (%) 12 (100%) 24/27 (88.9%) 1
MPH positive response 10/12 (83.3%) 20/24 (83.3%) 0.46
1 year
Sz occurrence 3 0
MPH 8/12 (66.7%) 20/24 (83.3%) 0.26
AED monotherapy 10 10
AED polytherapy 2 0
2 years
Sz occurrence 3 0
MPH 7/12 (58.3%) 19/24 (79.2%) 0.19
AED monotherapy 8 2
AED polytherapy 2 0
AED, antiepileptic drug; MPH, methylphenidate; IED, interictal epileptiform
discharges; Sz, epileptic seizures.1 year. Several short term studies have reported that MPH is safe to
use in both ADHD children with well controlled [25–27], and difﬁcult
to treat epilepsy [28–30], and that 61–73% of children with epilepsy
had beneﬁt from MPH. One study reported that use of combination of
a behavioral management and MPH 0.3–1 mg/kg/day for 3 months
improved ADHD symptoms in 61% of 18 patients with refractory
epilepsy [29]. Our ﬁnding was similar regarding the use of MPH. In
addition, we found no differences in maintenance on MPH at 1 and
2 years follow-up between the IED and the non-IED groups.
In recent studies it was suggested that clinicians appeared to be
reluctant to diagnose and initiate treatment for ADHD in children
with epilepsy [17,28]. We could not conﬁrm these ﬁndings. All our
children with epilepsy were initially treated with MPH and the
patients with epilepsy were assessed at younger age (8.5 years)
compared to the patients without epilepsy (10.3 years). One can
hypothesize that children with epilepsy may have more ADHD
symptoms which may contribute to early detection.
It may be difﬁcult to delineate ADHD symptoms from subtle
seizures, especially in cases with inattentive subtype of ADHD
which predominate in both epilepsy patients [2,15,31,32], and in
patients with IED [7]. Another enigmatic association is that
frequent IED (in more than 10% of the record) in the awake EEG can
impair cognitive performance in children [33], and in some cases
ADHD symptoms may be related to frequent epileptiform
discharges activated by sleep as previously reported [34–37]. In
these patients a careful assessment including neuropsychological
examination is needed before an eventual trial with AED. In our
study in order to clarify differential diagnosis, and treatment
choices an additional sleep EEG was performed in 15 and long-
term video-EEG monitoring in ﬁve cases. One of our cases had
continuous spike wave during slow sleep on EEG recording. This
case was treated with levetiracetam, but signiﬁcant reduction of
ADHD symptoms was not detected in this case.
In addition, one may be aware of the possibility of temporary
overtreatment with AEDs in cases with IED without conﬁrmed
epilepsy diagnosis. The patients with IED without epilepsy were
temporarily treated with AEDs during the ﬁrst year of follow up
(10 children) because this was a study on real-life patients. In these
cases the clinicians chose to treat due to uncertainty regarding
diagnosis. Our ﬁndings warranted caution regarding to assessment
and use of AED (in order not to overestimate the temporarily
occurrence of IED) in ADHD children with IED. Overall we believe
that our ﬁndings may have two implications for clinical practice:
(1) the use of MPH is safe in ADHD children with IED regardless of
previous history of epilepsy; (2) the maintenance on MPH was
similar in the groups of children with and without IED.
4.2. Limitations and strengths of study
The low number of cases with EA (n = 39) is a limitation in our
study as well as the lack of a prospective and randomized
controlled trial. We did not carry out a reliability test of diagnosis
or measure the exact dosage of MPH, which also are limitations of
our study. Strengths include the relatively large and unselected
cohort, as all children with suspected ADHD were referred to the
center. Our ﬁndings may be helpful to clinicians concerning MPH
as a safe treatment option in this group of patients. In order to
strengthen and conﬁrm these ﬁndings future studies might include
large and prospective samples within ADHD and IED, and who be
able to compare follow-up for large subgroups (with and without
previous epilepsy).
5. Conclusions
The study demonstrated that despite the occurrence of IED and
epilepsy the use of MPH for patients with ADHD was safe during
D. Socanski et al. / Seizure 25 (2015) 80–83 832 years of follow-up. IED predict the Sz occurrence in children with
previous epilepsy, but does not necessarily suggest an increased
seizure risk.
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